|
Comparison of α6 integrin and uPAR expression and clinicopathological findings |
||||
| Strong co-expression both of α6 integrin and uPAR |
ap value |
|||
|
|
||||
| Yes (n = 16) |
No (n = 26) |
0.011 |
||
|
|
||||
| Gender |
Male/Female |
11/5 |
16/10 |
N.S. |
| Age (year) |
64.4 ± 8.6 |
64.3 ± 9.5 |
N.S. |
|
| TNM stage |
I/II/III/IV |
2/1/6/7 |
7/4/12/3 |
N.S. |
| Location |
H/B, T |
12/4 |
20/6 |
N.S. |
| Liver metastasis |
Yes/No |
7/9 |
3/23 |
0.019 |
| Lymph node matastasis |
Yes/No |
13/3 |
13/13 |
0.045 |
| Cancer cell differentiation |
P/Muc/W/Mod |
1/0/4/11 |
2/3/13/8 |
N.S. |
| Retroperitoneal invasion |
Yes/No |
14/2 |
15/11 |
0.045 |
| Intrapancreatic nerve invasion |
Yes/No |
14/2 |
17/9 |
N.S. |
| Lymphatic system invasion |
Yes/No |
15/1 |
20/6 |
N.S. |
| Venous system invasion |
Yes/No |
15/1 |
20/6 |
N.S. |
|
uPAR, urokinase plasminogen activator receptor; H, head of pancreas; B, body of pancreas; T, tail of pancreas; P, papillary adenocarcinoma; Muc, mucinous carcinoma; W, well-differentiated adenocarcinoma; Mod, moderatery-differentiated adenocarcinoma. The pT, pN, and pM categories were determined according to the TNM classification [19]. The ap-values were obtained using the Mann-Whiteny U test. Values of age are given mean ± s.d. N.S., no significant. | ||||
Sawai et al. BMC Cell Biology 2006 7:8 doi:10.1186/1471-2121-7-8 |
||||